# OnCo record nct07415031 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07415031/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07415031", "NCT07415031" ;
  schema:name "A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies"@en ;
  schema:description "A phase 2 trial of Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Oxaliplatin in advanced solid tumours, run by Mirati Therapeutics Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07415031/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07415031> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-05-06" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/bms/> .